RU2016118021A - 2-(r2-тио)-10-[3-(4-r1-пиперазин-1-ил)пропил]-10н-фенотиазины для лечения бета-амилоидопатии или альфа-синуклеопатии и способ их диагностики или предварительной диагностики - Google Patents
2-(r2-тио)-10-[3-(4-r1-пиперазин-1-ил)пропил]-10н-фенотиазины для лечения бета-амилоидопатии или альфа-синуклеопатии и способ их диагностики или предварительной диагностики Download PDFInfo
- Publication number
- RU2016118021A RU2016118021A RU2016118021A RU2016118021A RU2016118021A RU 2016118021 A RU2016118021 A RU 2016118021A RU 2016118021 A RU2016118021 A RU 2016118021A RU 2016118021 A RU2016118021 A RU 2016118021A RU 2016118021 A RU2016118021 A RU 2016118021A
- Authority
- RU
- Russia
- Prior art keywords
- group
- groups
- amyloidopathy
- diagnosis
- examined
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 title claims 7
- 238000000034 method Methods 0.000 title claims 6
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 101000969812 Homo sapiens Multidrug resistance-associated protein 1 Proteins 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000005110 aryl thio group Chemical group 0.000 claims 3
- 125000004104 aryloxy group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- 229940088594 vitamin Drugs 0.000 claims 2
- 229930003231 vitamin Natural products 0.000 claims 2
- 235000013343 vitamin Nutrition 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000001431 Hyperuricemia Diseases 0.000 claims 1
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 229930182480 glucuronide Natural products 0.000 claims 1
- 150000008134 glucuronides Chemical class 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000003688 hormone derivative Substances 0.000 claims 1
- 150000002617 leukotrienes Chemical class 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000005070 sampling Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 230000001790 virustatic effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
- C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
- C07D279/28—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
- C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010044561 | 2010-09-07 | ||
| DE102010044561.4 | 2010-09-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013110018/04A Division RU2587154C2 (ru) | 2010-09-07 | 2011-08-30 | 2-(r2-тио)-10-[3-(4-r1-пиперазин-1-ил)пропил]-10h-фенотиазины для лечения бета-амилоидопатии или альфа-синуклеопатии, и способ их диагностики или предварительной диагностики |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016118021A true RU2016118021A (ru) | 2018-11-01 |
| RU2016118021A3 RU2016118021A3 (enExample) | 2020-02-26 |
Family
ID=44645670
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016118021A RU2016118021A (ru) | 2010-09-07 | 2011-08-30 | 2-(r2-тио)-10-[3-(4-r1-пиперазин-1-ил)пропил]-10н-фенотиазины для лечения бета-амилоидопатии или альфа-синуклеопатии и способ их диагностики или предварительной диагностики |
| RU2013110018/04A RU2587154C2 (ru) | 2010-09-07 | 2011-08-30 | 2-(r2-тио)-10-[3-(4-r1-пиперазин-1-ил)пропил]-10h-фенотиазины для лечения бета-амилоидопатии или альфа-синуклеопатии, и способ их диагностики или предварительной диагностики |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013110018/04A RU2587154C2 (ru) | 2010-09-07 | 2011-08-30 | 2-(r2-тио)-10-[3-(4-r1-пиперазин-1-ил)пропил]-10h-фенотиазины для лечения бета-амилоидопатии или альфа-синуклеопатии, и способ их диагностики или предварительной диагностики |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20130184268A1 (enExample) |
| EP (3) | EP2693216B1 (enExample) |
| JP (2) | JP6084924B2 (enExample) |
| CN (2) | CN103237802B (enExample) |
| BR (1) | BR112013005472A2 (enExample) |
| CA (2) | CA2870626C (enExample) |
| DE (2) | DE102010062810B4 (enExample) |
| DK (2) | DK2693216T3 (enExample) |
| ES (2) | ES2701453T3 (enExample) |
| MX (1) | MX357521B (enExample) |
| PL (2) | PL2693216T3 (enExample) |
| RU (2) | RU2016118021A (enExample) |
| WO (1) | WO2012031941A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI4335517T1 (sl) | 2016-07-25 | 2025-11-28 | Taurx Therapeutics Management Ltd. | Dajanje in odmerek diaminofenotiazinov |
| EP4385512B1 (en) | 2018-07-26 | 2025-12-03 | TauRx Therapeutics Management Ltd. | Optimised dosage of diaminophenothiazines in populations |
| WO2021188457A1 (en) * | 2020-03-16 | 2021-09-23 | Doublerainbow Biosciences Inc. | Etoposide glycosides, methods of making, and uses thereof as an anti-cancer drug |
| US20250082647A1 (en) * | 2022-01-04 | 2025-03-13 | Immungenetics Ag | Specific dosage of phenothiazine compounds for use in treatment or prevention of alzheimer's dementia |
| EP4605754A1 (en) * | 2022-10-18 | 2025-08-27 | Immungenetics AG | Identifying a subject suffering from alzheimer's dementia or being at risk of developing alzheimer's dementia |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH365379A (de) * | 1956-04-18 | 1962-11-15 | Sandoz Ag | Verfahren zur Herstellung von neuen, in 3-Stellung mit einer einwertigen Schwefelfunktion substituierten Phenothiazinen |
| BE568701A (enExample) * | 1957-06-18 | |||
| US3621097A (en) * | 1970-03-30 | 1971-11-16 | Jan Marcel Didier Aron Samuel | Method and compositions for treatment of mental illness |
| US4471116A (en) * | 1982-07-28 | 1984-09-11 | Hoffmann-La Roche Inc. | Substituted (10H-phenothiazin-10-L)-propyl-1-piperazines |
| US6566368B2 (en) * | 1994-04-22 | 2003-05-20 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage form for ameliorating male erectile dysfunction |
| WO1996004915A1 (en) * | 1994-08-08 | 1996-02-22 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes |
| DE4430091A1 (de) * | 1994-08-25 | 1996-02-29 | Bayer Ag | Verwendung von N-substituierten Phenothiazinen |
| DE60307049T2 (de) * | 2003-04-25 | 2007-02-08 | Neuro3D | Verwendung von Piperazin- Phenothiazin- Derivaten zur Herstellung eines Arzneimittels mit neuroprotektiven und/oder neurotropischen Wirkungen auf das ZNS und/oder PNS |
| DE102005014142B4 (de) * | 2005-03-23 | 2006-11-09 | Hennig Arzneimittel Gmbh & Co. Kg | Pelletförmige Retardzubereitung gegen Schwindel |
| WO2007062862A2 (en) * | 2005-12-02 | 2007-06-07 | Ludwig Maximilians Universität München | Use of calmodulin inhibitors for the treatment of neurodegenerative disorders |
| SI2457905T1 (sl) * | 2006-07-11 | 2016-12-30 | Wista Laboratories Ltd. | Postopki sinteze in/ali čiščenja diaminofenotiazinijevih spojin |
| CA2667155C (en) * | 2006-11-10 | 2016-05-10 | Cara Therapeutics, Inc. | Synthetic peptide amides |
| GB0701970D0 (en) * | 2007-02-01 | 2007-03-14 | Wilson Stuart | Treatment of protein aggregation diseases |
| TW200848063A (en) * | 2007-04-23 | 2008-12-16 | Combinatorx Inc | Methods and compositions for the treatment of neurodegenerative disorders |
| BRPI0911518A2 (pt) * | 2008-04-29 | 2017-06-13 | Pharnext | novas aproximações terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de resposta ao estresse de célula |
| CN102065858B (zh) * | 2008-04-29 | 2014-07-02 | 法奈科斯公司 | 使用唑尼沙胺和阿坎酸治疗阿尔茨海默病和相关病症的组合组合物 |
| LT2282778T (lt) * | 2008-04-29 | 2017-06-26 | Pharnext | Nauji terapijos būdai, gydant alzheimerio ligą ir susijusius sutrikimus per angiogenezės moduliaciją |
| CN107582551A (zh) * | 2009-05-14 | 2018-01-16 | 总医院公司 | 治疗退化性及缺血性疾病的方法和组合物 |
-
2010
- 2010-12-10 DE DE102010062810.7A patent/DE102010062810B4/de not_active Expired - Fee Related
-
2011
- 2011-08-30 DE DE102011053114A patent/DE102011053114A1/de not_active Ceased
- 2011-08-30 JP JP2013527544A patent/JP6084924B2/ja active Active
- 2011-08-30 EP EP13190419.5A patent/EP2693216B1/de active Active
- 2011-08-30 WO PCT/EP2011/064893 patent/WO2012031941A2/de not_active Ceased
- 2011-08-30 PL PL13190419T patent/PL2693216T3/pl unknown
- 2011-08-30 BR BR112013005472-7A patent/BR112013005472A2/pt not_active Application Discontinuation
- 2011-08-30 CA CA2870626A patent/CA2870626C/en active Active
- 2011-08-30 US US13/821,515 patent/US20130184268A1/en not_active Abandoned
- 2011-08-30 DK DK13190419.5T patent/DK2693216T3/en active
- 2011-08-30 CN CN201180053670.4A patent/CN103237802B/zh active Active
- 2011-08-30 CN CN201610631393.5A patent/CN106243060A/zh active Pending
- 2011-08-30 RU RU2016118021A patent/RU2016118021A/ru not_active Application Discontinuation
- 2011-08-30 PL PL11755294T patent/PL2614060T3/pl unknown
- 2011-08-30 CA CA2811454A patent/CA2811454C/en active Active
- 2011-08-30 EP EP11755294.3A patent/EP2614060B1/de active Active
- 2011-08-30 RU RU2013110018/04A patent/RU2587154C2/ru active
- 2011-08-30 DK DK11755294.3T patent/DK2614060T3/da active
- 2011-08-30 EP EP16180106.3A patent/EP3097914A3/de not_active Withdrawn
- 2011-08-30 MX MX2013002612A patent/MX357521B/es active IP Right Grant
- 2011-08-30 ES ES13190419T patent/ES2701453T3/es active Active
- 2011-08-30 ES ES11755294.3T patent/ES2605705T3/es active Active
-
2014
- 2014-09-29 US US14/499,918 patent/US9370523B2/en active Active
-
2015
- 2015-09-08 US US14/847,089 patent/US20150374711A1/en not_active Abandoned
-
2016
- 2016-07-01 JP JP2016131781A patent/JP6426663B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016118021A (ru) | 2-(r2-тио)-10-[3-(4-r1-пиперазин-1-ил)пропил]-10н-фенотиазины для лечения бета-амилоидопатии или альфа-синуклеопатии и способ их диагностики или предварительной диагностики | |
| Terbah et al. | Portal Hypertension in Malnutrition and Sarcopenia in Decompensated Cirrhosis—Pathogenesis, Implications and Therapeutic Opportunities | |
| UA137826U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
| UA138823U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
| UA138824U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
| UA138796U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
| UA138797U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
| UA138252U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
| UA138251U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
| UA138819U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
| UA131131U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
| UA122127U (uk) | Спосіб діагностики розвитку атеросклерозу | |
| UA140106U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
| UA138321U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
| UA138443U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
| UA121164U (uk) | Спосіб діагностики розвитку атеросклерозу | |
| UA121118U (uk) | Спосіб діагностики розвитку атеросклерозу | |
| WO2015015248A1 (en) | The use of compounds showing heat shock protein (hsp) co-inducing properties to enhance the insulin sensitizing effect in the treatment of type 2 diabetes | |
| UA138207U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
| UA138801U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
| UA138771U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
| UA121069U (uk) | Спосіб діагностики розвитку атеросклерозу | |
| UA138769U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
| UA140119U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
| UA121163U (uk) | Спосіб діагностики розвитку атеросклерозу |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200910 |